



**DRIVEN TO FULFILL THE
PROMISE OF BIOSIMILARS—
THE PFIZER WAY**

THE PFIZER PROMISE: *To help you provide patients with more treatment options while delivering the largest portfolio of potentially cost-saving biosimilars.¹⁻³*

Bringing Pfizer's legacy in oncology to biosimilars

Pfizer is committed to leveraging our global presence and expertise to bring biosimilars to oncology patients⁴

Offering a robust portfolio of novel cancer medicines that include originator biologics, small molecules, immunotherapies, and biosimilars^{4,5}

The potential of biosimilars for patients, payers and providers includes⁶⁻⁸:

Increased availability of biologics


Additional treatment choices at a potentially lower cost to the healthcare system

Healthcare system cost savings

Potential cost savings for the healthcare system

Expanded options for patients

Offer a variety of therapeutic options

A woman with blonde hair, wearing a teal sweater and a gold chain necklace, is looking at a doctor in a white lab coat. The doctor is holding a clipboard and looking at the woman. The background is a blurred indoor setting.

Biosimilars may potentially expand treatment options and deliver cost savings to meet the growing demand for biologic therapies.⁶

Pfizer leverages its legacy of innovation to produce high-quality biosimilars

Pfizer has the manufacturing, supply experience, and resources to develop and deliver biosimilar medicines⁴

Pfizer leverages more than 30 years of state-of-the-art manufacturing and supply-chain experience in biologics to reliably deliver biosimilars, which we have been providing to patients globally for over 12 years.

Pfizer oncology biosimilars are all produced to meet the same high-quality standards as its biologics, using the same robust protocols for monitoring quality throughout every stage of the manufacturing process.⁴

Continued dedication to advancing manufacturing and supply expertise⁴

120

logistics
centers

~9,500

supplier
partners

43

internal
manufacturing sites

Invested in the infrastructure to make an impact⁴

Pfizer is dedicating significant resources to building a sustainable future, with approximately \$5 billion in US-based capital projects over several years.

Pfizer is a leading provider of oncology biosimilars

Pfizer has the largest biosimilars portfolio in the US market, as of December 2020²

Pfizer has a robust portfolio, with 6 biosimilars of some of the world's most important cancer therapies and supportive care products approved by the FDA for oncology patients and is committed to supporting these treatment options for the US healthcare system.^{4,9}


At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 23 approved innovative cancer medicines and biosimilars across more than 30 indications.⁴



*Let's reach for
the full potential of
biosimilars, together*

Pfizer provides support to help with seamless biosimilar integration

Resources for providers and health systems to integrate biosimilars through effective operational enablement, IT, monitoring, education, and communication



Pfizer is committed to making your patients' support needs a priority. Together.

THIS IS **LIVING WITH** CANCER™

This Is Living With Cancer™ is a program designed for those who have been affected by cancer and those who love them. This program is available to anyone in the United States, regardless of tumor type or stage of disease, whether they're currently on a Pfizer Oncology treatment or not. Learn more at ThisIsLivingWithCancer.com.



LivingWith™ is a free app developed by Pfizer Oncology, designed to help patients and caregivers manage life with cancer. It is designed to help people connect with loved ones, ask for the help they need, remember important information from doctors' visits, and stay organized, all in one place. LivingWith is available in English and Spanish. Download **LivingWith™** for free. Visit ThisIsLivingWithCancer.com to learn more.



App Store is a service mark of Apple Inc., registered in the U.S. and other countries.
Google Play and the Google Play logo are trademarks of Google LLC.

Pfizer Oncology *together*™

At Pfizer Oncology Together™, patient support is at the core of everything we do. From helping to identify financial assistance options to connecting patients to resources for emotional support.



Breadth of Offerings

Pfizer has the largest portfolio of oncology biosimilars on the market to give more patients more treatment options²

A Robust Heritage in Oncology

Over 30 years of global experience with 23 approved oncology medicines⁴

Quality Focused

Pfizer oncology biosimilars are all produced to meet the same high-quality standards as its biologics⁴

References: **1.** IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. <https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf>. Accessed October 7, 2020. **2.** Drugs.com. How many biosimilars have been approved in the United States? <https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/>. Updated July 8, 2020. Accessed October 5, 2020. **3.** McGowan S, Jesse M. Biosimilars pipeline report. AmersourceBergen. https://www.amersourcebergen.com/-/media/assets/amersourcebergen/biosimilars-page/biosimilars-pipeline-report_061120.pdf?la=en&hash=353F4803D52AF60C2C9CCC8D4AD6C240790D1A02. Updated June 11, 2020. Accessed October 5, 2020. **4.** Data on file. Pfizer Inc., New York, NY. **5.** Pfizer Inc. Product pipeline. <https://www.pfizer.com/science/drug-product-pipeline>. Accessed October 5, 2020. **6.** Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. *Semin Oncol*. 2014;41(suppl 3):S13-S20. **7.** Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology. *Nat Rev Rheumatol*. 2012;8(7):430-436. **8.** Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. *J Am Acad Dermatol*. 2012;66(2):317-322. **9.** World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. <https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1>. Accessed October 5, 2020.

Visit PfizerBiosimilars.com to learn more about biosimilars